133 related articles for article (PubMed ID: 36727290)
1. Cytopathological features associated with POLE mutation in endometrial cancer.
Yanazume S; Iwakiri K; Kobayashi Y; Kitazono I; Akahane T; Mizuno M; Togami S; Tanimoto A; Kobayashi H
Cytopathology; 2023 May; 34(3):211-218. PubMed ID: 36727290
[TBL] [Abstract][Full Text] [Related]
2. "Surface epithelial slackening" pattern in endometrioid carcinoma: A morphological feature for differentiating the POLE mutation-subtype from the no specific molecular profile subtype.
Kitazono I; Akahane T; Yokoyama S; Kobayashi Y; Togami S; Yanazume S; Tasaki T; Noguchi H; Tabata K; Kobayashi H; Tanimoto A
Pathol Res Pract; 2023 Jul; 247():154563. PubMed ID: 37229919
[TBL] [Abstract][Full Text] [Related]
3. Cervical Cytology Preserves Histologically Detected Surface Epithelial Slackening, Unique to the
Kitazono I; Akahane T; Yokoyama S; Kubota E; Nishida-Kirita Y; Noguchi H; Murakami M; Yanazume S; Kobayashi H; Tanimoto A
In Vivo; 2024; 38(1):321-333. PubMed ID: 38148087
[TBL] [Abstract][Full Text] [Related]
4. Can endometrial cytology identify patients who would benefit from immunotherapy?
Yanazume S; Kirita Y; Kobayashi Y; Kitazono I; Akahane T; Mizuno M; Togami S; Tanimoto A; Kobayashi H
Acta Cytol; 2024 Mar; ():. PubMed ID: 38471464
[TBL] [Abstract][Full Text] [Related]
5. ATM immunohistochemistry as a potential marker for the differential diagnosis of no specific molecular profile subtype and POLE-mutation subtype endometrioid carcinoma.
Kitazono I; Kobayashi Y; Akahane T; Yamaguchi T; Yanazume S; Nohara S; Sakamoto I; Tabata K; Tasaki T; Kobayashi H; Tanimoto A
Pathol Res Pract; 2022 Feb; 230():153743. PubMed ID: 34954471
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study.
Yu S; Sun Z; Zong L; Yan J; Yu M; Chen J; Lu Z
J Gynecol Oncol; 2022 May; 33(3):e38. PubMed ID: 35320887
[TBL] [Abstract][Full Text] [Related]
7. Next-generation sequencing analysis of endometrial screening liquid-based cytology specimens: a comparative study to tissue specimens.
Akahane T; Kitazono I; Yanazume S; Kamio M; Togami S; Sakamoto I; Nohara S; Yokoyama S; Kobayashi H; Hiraki T; Suzuki S; Ueno S; Tanimoto A
BMC Med Genomics; 2020 Jul; 13(1):101. PubMed ID: 32652986
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.
León-Castillo A; Gilvazquez E; Nout R; Smit VT; McAlpine JN; McConechy M; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Soslow RA; Ganesan R; Matias-Guiu X; Oliva E; Harrison BT; Church DN; Gilks CB; Bosse T
J Pathol; 2020 Mar; 250(3):312-322. PubMed ID: 31829447
[TBL] [Abstract][Full Text] [Related]
9. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J
Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215
[TBL] [Abstract][Full Text] [Related]
10. Molecular Evaluation of Endometrial Dedifferentiated Carcinoma, Endometrioid Carcinoma, Carcinosarcoma, and Serous Carcinoma Using a Custom-Made Small Cancer Panel.
Kobayashi Y; Kitazono I; Akahane T; Yanazume S; Kamio M; Togami S; Nohara S; Sakamoto I; Yokoyama S; Tabata K; Kobayashi H; Tanimoto A
Pathol Oncol Res; 2021; 27():1610013. PubMed ID: 35002543
[TBL] [Abstract][Full Text] [Related]
11. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.
Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T
Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426
[TBL] [Abstract][Full Text] [Related]
12. TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
D'Alessandris N; Travaglino A; Santoro A; Arciuolo D; Scaglione G; Raffone A; Inzani F; Zannoni GF
Gynecol Oncol; 2021 Nov; 163(2):427-432. PubMed ID: 34446267
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
[TBL] [Abstract][Full Text] [Related]
14. Pelvic Carcinosarcoma Showing a Diverse Histology and Hierarchical Gene Mutation with a Common
Kitazono I; Akahane T; Kobayashi Y; Yanazume S; Tabata K; Tasaki T; Noguchi H; Kirishima M; Higashi M; Kobayashi H; Tanimoto A
Int J Surg Pathol; 2022 Dec; 30(8):891-899. PubMed ID: 35360975
[No Abstract] [Full Text] [Related]
15. Endometrial metaplasia: correlation of histological and cytological specimens obtained from 103 cases undergoing hysterectomy for endometrial carcinoma.
Toomine Y; Watanabe S; Ohishi Y; Tamiya S; Sugishima S; Kobayashi H; Oda Y; Kaku T
Cytopathology; 2014 Apr; 25(2):78-85. PubMed ID: 23517058
[TBL] [Abstract][Full Text] [Related]
16. Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study.
Dai Y; Zhao L; Hua D; Cui L; Zhang X; Kang N; Qu L; Li L; Li H; Shen D; Wang Z; Wang J
Front Immunol; 2022; 13():1035616. PubMed ID: 36532042
[TBL] [Abstract][Full Text] [Related]
17. The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations.
Willvonseder B; Stögbauer F; Steiger K; Jesinghaus M; Kuhn PH; Brambs C; Engel J; Bronger H; Schmidt GP; Haller B; Weichert W; Keller G; Noske A; Pfarr N; Boxberg M
Cancer Immunol Immunother; 2021 Jun; 70(6):1679-1689. PubMed ID: 33340331
[TBL] [Abstract][Full Text] [Related]
18. The clinicopathological characteristics of POLE-mutated/ultramutated endometrial carcinoma and prognostic value of POLE status: a meta-analysis based on 49 articles incorporating 12,120 patients.
Wu Q; Zhang N; Xie X
BMC Cancer; 2022 Nov; 22(1):1157. PubMed ID: 36357827
[TBL] [Abstract][Full Text] [Related]
19. Classification of Endometrial Carcinoma: New Perspectives Beyond Morphology.
Akhtar M; Al Hyassat S; Elaiwy O; Rashid S; Al-Nabet ADMH
Adv Anat Pathol; 2019 Nov; 26(6):421-427. PubMed ID: 31567131
[TBL] [Abstract][Full Text] [Related]
20. Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy.
Bakhsh S; Kinloch M; Hoang LN; Soslow RA; Köbel M; Lee CH; McAlpine JN; McConechy MK; Gilks CB
Histopathology; 2016 May; 68(6):916-24. PubMed ID: 26416160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]